CAS: 284035-33-2; (R)-2-Chloro-6-(2-Hydroxy-3-((2-Methyl-1-(Naphthalen-2-yl)Propan-2-yl)Amino)Propoxy)Benzonitrile

上下游产品

[2-methyl-1-(naphthalen-2-yl)propan-2-yl]amine 2-chloro-6-([(2R)-2-oxiranylmethyl]oxy)benzonitrile 2-(2-methyl-2-nitropropyl)naphthalene (+/-)-2-chloro-6-(3-chloro-2-hydroxypropoxy)benzonitrile

📜2-萘甲腈置于盐酸,Lithium Aluminium Tetrahydride,Sodium Methylate,锌体系中,用 乙醚,乙醇,水,甲苯 用作溶剂,化学反应 38.33H,反应生成2-氯-6-[(2R)-3-[[1,1-二甲基-2-(2-萘基)乙基]氨基]-2-羟基丙氧基]苯腈
参考文献:Synthesis Of The Calcilytic Ligand Nps 2143
标题:Synthesis Of The Calcilytic Ligand Nps 2143
摘要:(R)-3(nps 2143)是人类钙感受受体(casr)的负向变构调节剂,因此代表了一个重要的药理学工具化合物,用于研究casr.在此,我们首次披露了对(R)-3的完整实验描述,详细表征和对对映体纯度的评估.我们提出了一种高效,可重复和可扩展的(R)-3合成方法,只需要最少的色谱纯化步骤.通过手性HPLC表明(R)-3的光学纯度非常高(er > 99:1),而且(R)-3的药理学特性完全符合文献报道.
Doi:10.3762/bjoc.9.154

专利信息

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.